Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Law Causes Roche To Hesitate On Oncology Price Increases

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche and Genentech were "circumspect" about implementing price increases given the confusion over Medicare reimbursement, Roche Worldwide Pharmaceuticals Head Burns says. European prices for the companies' oncology products drop.

You may also be interested in...



Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says

The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.

Roche's Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP

Centers for Medicare & Medicaid Services raises Xeloda's reimbursement rate from 85% of AWP based on data submitted by Roche. CMS also corrects payment allowance for the company's CellCept.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Topics

UsernamePublicRestriction

Register

PS059191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel